Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Influence of Adherence to Growth Hormone Therapy (GHT) With Norditropin® on Near Final Height in Patients With Growth Hormone Deficiency (GHD) and Born Small for Gestational Age (SGA)
- Conditions
- Growth Hormone Deficiency in ChildrenBorn Small for Gestational Age
- Interventions
- First Posted Date
- 2019-06-03
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 750
- Registration Number
- NCT03972345
- Locations
- 🇩🇪
Universitätsklinikum Ulm für Kinder- und Jugendmedizin, Ulm, Germany
A Study to Look at How Safe NNC0268-0965 is in Healthy People and People With Type 1 Diabetes
Phase 1
Completed
- Conditions
- Healthy VolunteersDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2019-05-28
- Last Posted Date
- 2021-01-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 78
- Registration Number
- NCT03965013
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
A Study of All-Cause and Cardiovascular Mortality in Type 2 Diabetes Patients Using Basal Insulin Detemir and Glargine
- First Posted Date
- 2019-05-23
- Last Posted Date
- 2019-07-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 12847
- Registration Number
- NCT03960814
- Locations
- 🇩🇰
Novo Nordisk Investigational Site, Bagsværd, Denmark
A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before
Phase 2
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2019-05-15
- Last Posted Date
- 2021-04-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 205
- Registration Number
- NCT03951805
- Locations
- 🇪🇸
Novo Nordisk Investigational Site, Vic (Barcelona), Spain
A Research Study of How Overdosing of a New Once Weekly Medicine NNC0148-0287 C (Insulin 287) Influences the Blood Sugar Level in People With Type 2 Diabetes
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2019-05-10
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 43
- Registration Number
- NCT03945656
- Locations
- 🇦🇹
Novo Nordisk Investigational Site, Graz, Austria
A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice (SURE NETHERLANDS)
- First Posted Date
- 2019-04-29
- Last Posted Date
- 2023-01-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 218
- Registration Number
- NCT03929679
- Locations
- 🇳🇱
Novo Nordisk Investigational Site, Zwijndrecht, Netherlands
Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition
Phase 2
Completed
- Conditions
- Chronic Kidney DiseasesInflammation
- Interventions
- Biological: Ziltivekimab
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 264
- Registration Number
- NCT03926117
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Kenosha, Wisconsin, United States
A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine
Phase 2
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Insulin glargine U100
- First Posted Date
- 2019-04-22
- Last Posted Date
- 2022-01-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 154
- Registration Number
- NCT03922750
- Locations
- 🇮🇹
Novo Nordisk Investigational Site, Roma, Italy
A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Placebo (semaglutide)
- First Posted Date
- 2019-04-16
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 9642
- Registration Number
- NCT03914326
- Locations
- 🇹🇷
Eskisehir Osmangazi University School of Medicine, Eskisehir, Turkey
🇹🇷Haseki Egitim ve Arastirma Hastanesi_ISTANBUL, Istanbul, Turkey
🇹🇷Kanuni Sultan Suleyman Egitim ve Arastirma Hastanesi, Istanbul, Turkey
A Study to Compare the Uptake Into the Blood of Two Strengths of Somapacitan After Injection Under the Skin in Healthy Subjects
- First Posted Date
- 2019-04-05
- Last Posted Date
- 2019-08-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 33
- Registration Number
- NCT03905850
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
© Copyright 2025. All Rights Reserved by MedPath